Related Experiment Video
Updated: Oct 26, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
Key Challenges on the Path toward Precision Immunotherapy for Large B-cell Lymphoma
Xubin Li1, Christopher R Flowers1, Michael R Green1,2
1Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract:
Cell and immune therapies have transformed the outcomes of patients with lymphoma, but the majority of patients do not have durable benefit. Here, we provide our perspective on key challenges in personalizing cell and immune therapy approaches for lymphoma through discovery, validation, and clinical deployment of microenvironment classification.
Related Concept Videos
Tumor Immunotherapy
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cells of the Adaptive Immune Response
